Saturday, July 5, 2025 7/5/2025

Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy

Award Number: R01CA260274
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2022
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy - Abstract The immune system can distinguish healthy cells from tumor cells, as the latter expresses tumor associated antigens (TAAs). In the context of CD8+ T cell-mediated immune responses, recognition of TAAs occurs through the presentation of TAAs via major histocompatibility class I (MHC-I) on tumor cells and their interaction with T- cell receptor (TCR) on the CD8+ T cells. Impairing this event will ultimately reduce or annihilate the CD8+ T-cell mediated tumor cytotoxicity. However, reduction or loss of antigen presentation is a frequent and essential mechanism used by tumor cells to escape immune recognition and destruction, including genomic deletion of MHC-I genes, transcriptional suppression of antigen presentation-associated genes, and dysregulation of tumor antigen processing by 26S immunoproteasome. Despite the recent success in immunotherapies based on direct blockade of immune checkpoint proteins (PD-1, CTLA-4 and PD-L1), a majority of patients with solid tumors do not experience durable clinical benefits. The mechanisms of tumor resistance against immune checkpoint blockade (ICB) involve low levels of tumor infiltrating lymphocytes, suppressive immune cells (Tregs, MDSCs and macrophages), and adverse tumor microenvironment. Aberrations in the antigen processing and presentation machinery (APM) genes correlate with poor clinical outcomes. Therefore, therapeutic intervention of tumor antigen presentation would be a promising therapeutic approach to improve responsiveness towards immune checkpoint blockade. In a screen for small-molecule compounds from herbal medicine that potentiate T cell-mediated cytotoxicity, we identified atractylenolide I (ATT-I) that significantly promotes tumor antigen presentation of both human and mouse colorectal cancer cells and thereby enhances the cytotoxic response of CD8+ T cells. In syngeneic mouse colorectal tumor models, treatment of ATT-I in combination with PD-1 antibody markedly enhanced the efficacy of immune checkpoint blockade therapy. We propose that targeting the function of immunoproteasome with ATT-I promotes tumor antigen presentation, empowers T-cell cytotoxicity, and thus elevates the tumor response to immunotherapy. In this application, we will 1) determine the molecular mechanism by which ATT-I promotes antigen processing and presentation in colorectal cancer cells; 2) evaluate the effect of ATT-I treatment on intra-tumor immune cell infiltration, activity of cytotoxic T lymphocytes, and their interaction with tumor microenvironment in colorectal tumors; 3) assess the therapeutic activity of ATT-I in enhancing the efficacy of immune checkpoint blockade immunotherapy (ICB) using genetically engineered mouse models of colorectal cancer and human ex vivo colorectal tumor organoid models.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $501,827 )
2025	2025	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Treatment Research	001	4	5/30/2025	NON-COMPETING CONTINUATION	$50,182
2025	2025	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Treatment Research	000	4	1/7/2025	NON-COMPETING CONTINUATION	$451,645
														Subtotal = $501,827

Issue Date FY: 2024 ( Subtotal = $476,736 )
2024	2024	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Treatment Research	000	3	1/8/2024	NON-COMPETING CONTINUATION	$451,645
2024	2024	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Treatment Research	002	3	4/18/2024	NON-COMPETING CONTINUATION	$25,091
2024	2024	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Treatment Research	001	3	4/12/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $476,736

Issue Date FY: 2023 ( Subtotal = $491,792 )
2023	2023	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Treatment Research	001	2	3/21/2023	NON-COMPETING CONTINUATION	$40,147
2023	2023	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Treatment Research	000	2	12/21/2022	NON-COMPETING CONTINUATION	$451,645
														Subtotal = $491,792

Issue Date FY: 2022 ( Subtotal = $501,827 )
2022	2022	TRUSTEES OF INDIANA UNIVERSITY	980 INDIANA AVE RM 2232	INDIANAPOLIS	IN	46202	MARION	USA	Cancer Treatment Research	000	1	12/31/2021	NEW	$501,827
														Subtotal = $501,827

Grand Total All Awards = $1,972,182

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy

Award Number: R01CA260274

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2022

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer